Prolotherapy and Platelet Rich Plasma Therapies (for New Jersey Only)
This policy governs coverage determinations for prolotherapy and platelet-rich plasma (PRP) therapies for members in New Jersey; it applies to clinical use and billing for these regenerative injection therapies.
Policy Summary
PayerUnitedHealthcare
PolicyProlotherapy and Platelet Rich Plasma Therapies (for New Jersey Only)
Added notation to indicate HCPCS code P9020 is not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program.
Updated Clinical Evidence and References sections to reflect the most current information.
Archived previous policy version CS103NJ.S.
2therapies listed as not medically necessary
NJpolicy application state
multipleclinical topics cited
severalcodes listed
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
P9020
HCPCS P9020 NJ Medicaid risk
Coverage Determinations and Evidence Summary
inv-01: Not Medically Necessary
Covered when ALL of the following are met:
Primary stance: Prolotherapy and platelet-rich plasma are unproven and not medically necessary for any condition or indication.
Policy states insufficient evidence of efficacy for both therapies.
inv-02: Evidence summaries (no explicit coverage rules in excerpt)
Evidence-based findings summarized (no explicit coverage decision text in this segment):
Knee Osteoarthritis: Systematic reviews and RCTs show mixed results: some meta-analyses and RCTs report modest pain/function benefit of dextrose prolotherapy (DPT) or PRP versus controls at some time points, but high-quality trials and pooled analyses report inconsistent benefits and substantial heterogeneity across studies.
Examples: Wee et al. (2021) included 11 trials (n=837) and found potential pain benefits but high risk of bias; limitations include heterogeneity in injection sites, concentrations, and outcome measures.
Lateral epicondylosis: Randomized trials and a large recent RCT (Lhee et al. 2025, n=231) report that PRP and prolotherapy improved DASH scores and patient satisfaction versus physiotherapy/ESWT over 24 months; meta-analyses (Zhu et al. 2022) found DPT reduced pain and improved function at 12 weeks with modest effect sizes.
Limitations include varying comparators, small trials in pooled analyses, and methodological heterogeneity.
Finger (first carpometacarpal) OA: Single randomized trials suggest dextrose may outperform corticosteroid at intermediate follow-up (6 months), but evidence is limited to small RCTs.
Example: Jahangiri 2014 (small trial).
inv-03: Coverage evidence synthesis
Summary of evidence-based coverage considerations (evidence quality and typical findings):
Lateral epicondylosis: Dextrose prolotherapy demonstrates short-term reductions in pain and improvements in function in several small RCTs and meta-analyses; a recent large RCT reported clinically meaningful DASH improvements for PRP and prolotherapy versus physiotherapy over 24 months, but heterogeneity and study limitations persist.evidence moderate to low
See Zhu et al. (2022) pooled SMD -0.44 at 12 weeks and Lhee et al. (2025) RCT n=231.
Rotator cuff tendinopathies: Some RCTs report improved pain and function with prolotherapy versus exercise or saline in small trials, including sustained benefit at 1 year in one study, but systematic reviews note methodological limitations and inconsistent findings versus corticosteroid.evidence low to inconsistent
See Ewart et al. (2024) and Seven et al. (2017).
Groin pain (adductor-related):
inv-04: Evidence summaries
Evidence summaries and conclusions reported in the cited studies and reviews
Temporomandibular joint disorders - prolotherapy evidence: Multiple systematic reviews and RCTs report dextrose prolotherapy reduces TMJ pain and can improve jaw mobility versus placebo or comparators up to 12 months, though studies are small and heterogeneous.
See Sit et al. (2021), Bahgat et al. (2025), Louw et al. (2019).
Lower limb tendinopathies: Observational studies and some controlled trials report pain and function improvements with prolotherapy for Achilles and ankle conditions, but evidence is uncontrolled or limited and higher-quality RCTs are needed.
See Bello Baez et al. (2023), Morath et al. (2018).
PRP general statement: PRP preparations are heterogeneous, lack standardization, and overall evidence fails to consistently substantiate clinical efficacy across many indications; higher-quality, standardized trials with longer follow-up are required.
See Hayes (2022) assessment and chunk 67.
inv-05: Evidence summaries by indication
Evidence-based considerations summarized from multiple systematic reviews and RCTs relevant to coverage decisions:
Knee osteoarthritis evidence summary: Some meta-analyses and RCTs report PRP provides statistically and sometimes clinically significant improvements in pain and function versus placebo or HA at 6–12 months, but overall evidence quality is low and heterogeneous; benefits may be partial and increase over time in some analyses.clinically significant improvement typically assessed at 6–12 months using validated scores
Filardo et al. and ECRI found benefits but noted low-quality evidence and heterogeneity.
Hip osteoarthritis evidence summary: Available RCTs and assessments do not demonstrate consistent clinically meaningful benefit of PRP over saline or HA at short-term follow-up; evidence is small and low quality.follow-up up to 6–12 months assessed
Hayes (2019) and Gazendam et al. (2020) concluded potential but unproven benefit.
Tendinopathy and soft tissue indications:
inv-06: Evidence synthesis — implications for coverage
evidence_summary: Multiple systematic reviews and RCTs show mixed results: PRP may offer short-term pain and function benefits for some indications (plantar fasciitis, lateral epicondylitis, certain tendinopathies) but evidence is heterogeneous, of low-to-very-low certainty, and long-term advantages are inconsistent; PRP can have higher rates of transient post-injection pain in some settings.
Use clinical judgment; standardized PRP protocols lacking; see Herbert et al., Fucaloro et al., Hayes reviews.
inv-07: Wound therapy evidence summary
Evidence-summary driven stance across wound indications
Wound indications (DFUs): Systematic reviews and technology assessments indicate PRP may increase complete wound closure in diabetic foot ulcers compared with standard wound care, but heterogeneity in protocols and variable study quality limit definitive conclusions.moderate SOE for DFUs
Hayes and ECRI reports indicate potential benefit but call for standardized protocols and more RCTs.
inv-08: Foot/ankle adjuncts
Foot/ankle adjunctive therapy
PRP or HA as adjunct to arthroscopic microperforation: Small trials and meta-analysis report no significant differences in VAS/AOFAS when HA is added; PRP may show slight non-significant improvements overall, with individual small RCTs reporting benefits favoring PRP, but evidence is inconclusive.inconclusive
Basciani et al. (2024) and Görmeli et al. (2015) summarize small heterogeneous studies.
inv-09: Low back pain
Low back pain (discogenic, facet, SIJ, nonspecific) evidence summary
PRP for chronic low back pain: Multiple small RCTs and systematic reviews report mixed results: some trials show short- or mid-term improvements in pain and disability versus steroids, lidocaine, or placebo while others show no benefit; sample sizes are small and PRP preparation and injection protocols vary widely.inconclusive
Zhang et al. (2024) network meta-analysis and multiple RCTs (Singh 2023, Won 2022, Tuakli-Wosornu 2016) report heterogeneous findings and limited evidence.
inv-10: Evidence summaries and guideline positions
Summary of guideline and evidence positions in this document segment
Wounds (PRP/PRF): Systematic reviews report mixed RCT results; some analyses (Miron et al.) report positive wound-healing findings in a majority of studies but RCT data are conflicting; meta-analyses (Martinez-Zapata, Qu et al.) suggest possible benefit in diabetic foot ulcers but overall evidence is low quality and inconclusive.evidence mixed; RCTs conflicting
See Miron et al. (2017), Martinez-Zapata (2016), Qu et al. (2020).
inv-11: Guideline consensus and conflicts
Selected society guideline stances
Knee osteoarthritis (PRP): Guidelines conflict: AAOS (2022) notes PRP may reduce pain/function based on low-quality evidence; NICE (2019) recommends use only with special arrangements; VA/DoD (2020) finds insufficient evidence; AAHKS (2019) does not recommend biologics for advanced arthritis; ACR (2019) strongly recommends against PRP for knee/hip OA.guideline conflict
Multiple society positions reflect low-to-very-low evidence and differing recommendations.
Rotator cuff and shoulder conditions: AAOS (2019) finds limited evidence not to support routine use of PRP for rotator cuff tendinopathy or partial tears and strong evidence against biologic augmentation of rotator cuff repair for improving patient-reported outcomes, although limited data suggest liquid PRP may reduce retear rates.limited supporting evidence
Not routinely recommended.
Low back and spine (PRP):
UnitedHealthcare considers prolotherapy and platelet‑rich plasma (PRP) to be not medically necessary for any condition or indication due to insufficient evidence of efficacy. This policy stance applies across indications and is the basis for coverage determinations and potential claim denials for these therapies in the absence of stronger supporting data.
This document does not list discrete procedural coverage exclusions. Study eligibility criteria reported in trials commonly excluded participants with active infection and other conditions that would confound safety or efficacy assessments (for example, some KOA trials excluded Kellgren‑Lawrence grade 1 and 4 or recent injections). Those trial exclusion items are research eligibility criteria and are not presented as coverage policy exclusions.
The evidence base is limited by short follow‑up, small sample sizes, heterogeneous methods, and risk of bias across trials. These limitations — including lack of robust long‑term outcome data and variability in study design — are repeatedly noted and underscore the need for further investigation before clinical usefulness can be established for many indications.
No explicit procedural exclusions are specified in the cited excerpts. However, the literature highlights substantial lack of standardization in PRP and prolotherapy preparations and protocols; this heterogeneity and insufficient evidence preclude endorsement of standardized procedural use at this time.
Although specific exclusions are not listed in these segments, the document emphasizes insufficient evidence for long‑term benefit in certain indications (for example, hip OA and many tendinopathies). Where evidence remains inconclusive, routine coverage is not supported pending higher‑quality data.
Clinical studies and systematic reviews frequently did not standardize PRP composition or preparation methods and generally did not assess safety of multiple‑injection series. As a result, there is limited evidence regarding the safety and efficacy of repeated or serial PRP treatments and uncertainty about long‑term outcomes after multiple injections.
Evidence is insufficient to generalize PRP use to venous leg ulcers and many other chronic wound types. Systematic reviews and technology assessments report few and heterogeneous trials, making it uncertain whether routine use of PRP is effective for these wound indications.
NICE guidance specifies that autologous PRP gel should not be offered for diabetic foot problems outside clinical trials, and that PRP injections for knee osteoarthritis should only be used with special arrangements for clinical governance, consent, and audit or research due to limited quality of evidence.
Administrative note: HCPCS code P9020 is not listed on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program; providers should verify state fee‑schedule and benefit plan coverage before billing.
Overall, prolotherapy and PRP are considered investigational/unproven and therefore not medically necessary across indications because current evidence is inconsistent, heterogeneous, and does not reliably demonstrate sustained clinical benefit.
Multiple systematic reviews and meta‑analyses document inconsistent efficacy findings and substantial methodological heterogeneity across PRP and prolotherapy studies. Variability in preparation, leukocyte content, injection protocols, and outcome reporting contributes to low or very low certainty of evidence for many indications.
Some excerpts do not make blanket 'not medically necessary' statements for every specific indication but instead emphasize that evidence is inconclusive, of low quality, and that further rigorous trials are needed before routine clinical adoption can be recommended.
The large randomized trial by Bennell et al. found no difference between intra‑articular PRP and saline placebo for symptoms or joint structure at 12 months in participants with mild‑to‑moderate medial knee osteoarthritis, illustrating the potential for high‑quality trials to show no benefit.
Hip osteoarthritis trials and systematic reviews to date do not demonstrate clinically meaningful benefit of PRP over saline or hyaluronic acid at short‑term follow‑up; evidence is small and low quality and does not support routine use.
For several musculoskeletal indications — including Achilles tendinopathy and many nonoperative rotator cuff conditions — randomized trials and systematic reviews do not show consistent, durable benefit for PRP or prolotherapy. The overall evidence for these indications is low to very low and insufficient to support routine clinical use.
For chronic wounds and certain musculoskeletal soft‑tissue indications the evidence remains inconclusive. Meta‑analyses and technology assessments report mixed results and heterogeneity across trials; routine use of PRP for many wound types is not supported without higher‑quality, standardized studies.
The American College of Rheumatology (2019) guideline strongly recommends against PRP treatment for knee and/or hip osteoarthritis and conditionally recommends against prolotherapy for these indications, reflecting guideline‑level skepticism for routine use in OA.
Applicable Procedure and Billing Codes
Documentation Required
Provider Action Callout
Provider action notes and billing implications to watch for regarding coding and coverage for therapies discussed in this policy segment.
Provider action: None specified in this segment; no procedure-specific authorization steps are detailed in this excerpt.
Provider action: Not applicable in this excerpt — no explicit prior authorization triggers or preauthorization criteria are provided here.
Provider action: No explicit authorization triggers or prior authorization pathways are defined in this policy segment.
Provider action: Evidence limitations and study heterogeneity (variable protocols, concentrations, injection techniques, and outcomes) may trigger documentation requests or medical review to support medical necessity.
Provider action: Complication risk (e.g., injection-site pain, ecchymosis, potential procedural risks) may affect authorization decisions and should be documented in the medical record.
Provider action: Evidence heterogeneity (including mixed results vs saline/placebo and small, short-duration RCTs) may trigger denials when clinical benefit is uncertain or not well-documented.
Provider action: Off-label use and regulatory note — some uses of PRP/prolotherapy for indications discussed may be off-label; document rationale and prior conservative therapy attempts.
Prior Authorization, Documentation, and Billing Guidance
Billing Rule
Listed procedure and HCPCS codes (reference)
The policy provides a list of procedure and HCPCS/CPT codes for reference; listing does not guarantee coverage or payment and benefit determination is governed by federal, state, or contractual requirements.
Example referenced codes: 0232T (PRP injection), G0460/G0465 (autologous PRP for wounds), M0076 (prolotherapy), P9020 (PRP unit).
Inclusion in the policy does not imply right to reimbursement.
Prior Authorization
Prior authorization: not specified in this excerpt
This excerpt does not state specific prior authorization requirements for prolotherapy or PRP procedures.
Key Definitions and Preparations
Prolotherapy definition — injection substances
Prolotherapy — general definitionInjection of any substance (e.g., dextrose, saline, sarapin, procaine, or lidocaine) to promote growth of normal cells or connective tissue by stimulating an inflammatory healing response
Common injectatesDextrose, saline, local anesthetic (procaine or lidocaine), sarapin — used alone or in combination
Treatment intentDirected injections to injury sites to elicit mild inflammation and encourage regrowth and strengthening of ligaments/tendons
Platelet-rich plasma (PRP) definition
PRP — core definitionAn autologous blood preparation with a high platelet concentration and concentrated platelet-derived growth factors and cytokines intended to stimulate tissue regeneration
Preparation variability
Background and Mechanism
Background: Prolotherapy refers to injection of solutions (for example, hypertonic dextrose, saline, or local anesthetic) intended to provoke a local inflammatory response to stimulate healing and strengthen connective tissue. Preparations, concentrations, and injection techniques vary across studies, contributing to heterogeneity of evidence.
Policy Version History
2026-02-01policy_revisionLatest
Applicable codes updated and notation added that HCPCS code P9020 is not on the State of New Jersey Medicaid Fee Schedule (may not be covered); Clinical Evidence and References were updated; previous policy version CS103NJ.S archived.
Policy Summary
PayerUnitedHealthcare
PolicyProlotherapy and Platelet Rich Plasma Therapies (for New Jersey Only)
Evidence is limited (small numbers) but case series and reviews report symptom improvement; overall data are insufficient for firm conclusions.
evidence low
See Bisciotti et al. (2020) summary.
Temporomandibular joint disorders: Systematic reviews and RCTs suggest hypertonic dextrose prolotherapy reduces TMJ pain and may improve mouth opening up to 12 months, but trials are small and heterogeneous, limiting generalizability.evidence low to moderate
See Bahgat et al. (2025), Sit et al. (2021), and related RCTs.
Knee osteoarthritis - mixed findings: Systematic reviews/meta-analyses report some benefits of PRP versus placebo or HA at certain time points (6–12 months) but high-quality RCTs (e.g., Bennell et al.) show no difference versus saline at 12 months; evidence quality is low and heterogeneous.
See Filardo et al. (2021), Bennell et al. (2021), Lin et al. (2019), Dório et al. (2021).
Evidence is mixed: PRP or prolotherapy may show benefit for some tendinopathies (eg, lateral epicondylitis, patellar) in some trials but evidence for Achilles and rotator cuff tendinopathy is inconsistent; systematic reviews grade certainty as low or very low.
outcomes measured at 3–12 months
See Masiello et al. (2023), Balasubramaniam et al., and Hayes reviews.
Surgical augmentation (ACLR, meniscal repair): PRP used as an adjunct in ACL reconstruction or meniscal repair shows occasional short-term improvement but no proven long-term benefits in healing or failure rates; evidence is low to very low.most trials report outcomes up to 12 months
See Zhu et al. and Migliorini et al. summaries.
Safety and complications: PRP is generally well tolerated but may have higher rates of transient post-injection pain and local adverse events compared with comparators in foot/ankle studies; serious complications are rare in reported trials.number needed to harm ~13 for any complication in foot/ankle PRP vs alternatives
Fucaloro et al. reported higher post-injection pain and NNH=13.
ASIPP (2019) states Level III evidence for intradiscal PRP and Level IV for facet, epidural, and SIJ PRP injections and notes regenerative therapy may be provided with other modalities and appropriate precautions.
limited evidence
Consider in context of other therapies and precautions.
Provider action: NJ Medicaid coverage risk for P9020 — P9020 is not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program; confirm state-specific coverage prior to billing.
Provider action: No step therapy pathways are defined in this policy segment.
Clinical trials cited used eligibility criteria (e.g., Kellgren-Lawrence grade) but no payer prior authorization rules are specified.
Prior Authorization
Prior authorization — no explicit requirements stated
No explicit prior authorization requirements are described in the referenced document sections.
The policy summarizes evidence and codes but does not define mandatory PA workflows in these chunks.
Prior Authorization
Prior authorization not specified
The document does not provide mandatory prior authorization rules; it emphasizes evidence limitations rather than administrative PA mandates.
No billing codes or compulsory PA triggers are specified in these excerpts.
Prior Authorization
Prior authorization: clinical rationale and procedural details
When prior authorization is used, it should require clinical rationale and procedural details because PRP and prolotherapy protocols are heterogeneous and evidence is inconsistent.
Include indication, prior conservative therapies tried, intended PRP/preparation protocol (e.g., leukocyte-rich vs leukocyte-poor), number/timing of injections, and use of image guidance.
Prior Authorization
Prior authorization recommended when evidence is inconsistent
Given inconsistent and low-quality evidence with variable protocols, the policy recommends prior authorization include documentation of persistent symptoms after conservative therapy and explicit PRP/procedure details to support medical necessity determinations.
Demonstrate failure or inadequate response to conservative care and specify expected timeframe for benefit.
Prior Authorization
Prior authorization required for PRP therapies (expected)
For PRP therapies in wound and spine indications (where evidence and protocols vary), prior authorization is expected to evaluate indication, prior conservative therapy, and PRP preparation details.
PA should assess heterogeneity of PRP protocol and clarify intended application (e.g., topical gel vs injection).
Prior Authorization
Prior authorization may be required — include regulatory/device info
When interventions involve devices, drugs, or biologic components with separate regulatory status, obtain prior authorization per payer rules and provide device/drug regulatory information as requested.
Agents used (e.g., dextrose, lidocaine) may be used off-label for prolotherapy — document intended use and regulatory status if relevant.
Prior Authorization
Prior authorization and benefit verification — check governing plan
Verify prior authorization and benefits against the member's federal, state, or contractual benefit plan; UnitedHealthcare may use third-party tools to assist benefit administration.
Coverage depends on governing plan documents and may differ across lines of business and states.
Note
Provider action — miscellaneous
No specific miscellaneous provider action is specified in this excerpt.
Step Therapy
No step therapy pathways defined in this segment
No formal step therapy pathways are defined in this policy segment; comparators in the evidence base include exercise, saline, PRP, corticosteroids, and hyaluronic acid.
Comparative evidence does not translate into a defined step therapy algorithm in this excerpt.
Step Therapy
Step therapy context — often used after first-line failure
Studies often enrolled patients who were refractory to first-line treatments, implying that PRP/prolotherapy is generally considered after failure of conservative care rather than as first-line therapy.
Document prior conservative treatments when considering advanced or investigational injections.
Step Therapy
No step therapy algorithms described
This excerpt does not describe any step therapy algorithms or required prior conservative steps in a formal pathway.
PRP and prolotherapy are typically considered when conservative therapies (oral medications, physical therapy) are contraindicated, unavailable, or ineffective; providers should document failed conservative management.
Evidence reviews note PRP may be appealing when conservative therapies fail but do not define mandatory steps.
When PRP or prolotherapy is considered, providers should document failure or inadequate response to standard conservative treatments (e.g., physical therapy, NSAIDs, corticosteroid injection) before proceeding.
Include dates, duration, and response to prior therapies in the medical record.
Step Therapy
Conservative therapy prior to PRP — spine trials context
Several spine-related trials compared PRP with standard conservative injections (steroid, local anesthetic) and reported mixed results, supporting the expectation that conservative spine care is typically tried prior to PRP interventions.
Document prior spine injections and their outcomes when requesting further interventions.
Step Therapy
Conventional therapy before biologics — consider conventional management first
Clinical guidance and some society statements suggest considering conventional measures (exercise, PT) before or alongside regenerative therapies; document the use and response to conventional care.
Regenerative therapy may be provided independently or with conventional therapies per guideline context.
Note
Provider action — miscellaneous
No miscellaneous provider action is specified in this excerpt.
Billing Rule
Coding and documentation note — listing does not guarantee coverage
Listing codes in the policy is for reference only; presence of a code does not guarantee coverage and benefit determination is governed by federal, state, or contractual requirements.
Providers should verify coverage and reimbursement with the applicable payer and plan.
Documentation Required
Outcome measures commonly reported in trials (document when possible)
Outcome measures commonly reported in the trials include VAS, WOMAC, KOOS, and performance-based measures such as walking speed, stair-climb time, chair-rise time, and DASH/Q-DASH.
Document baseline and follow-up scores when available to support clinical decisions and potential authorization requests.
Documentation Required
Documentation expectations from clinical studies — diagnostic confirmation and image guidance
Clinical studies typically required diagnostic confirmation (for example, clinical diagnosis of tendinopathy) and often used ultrasound guidance; concurrent physical therapy or home exercise programs were commonly reported and should be documented when used.
Include diagnostic imaging or exam findings, ultrasound guidance use, and concurrent therapies in the record.
Documentation Required
Suggested clinical documentation — imaging and specialist evaluation details
Suggested clinical documentation includes baseline imaging and validated pain/function scores; some trials required MRI for certain indications (e.g., TMJ internal derangement) and standardized outcome measures.
When available, include MRI, ultrasound reports, and validated scores (e.g., VAS, WOMAC, KOOS) in documentation.
Documentation Required
Required clinical outcome and procedural detail documentation for sustained benefit claims
To support claims of sustained clinical benefit, provide baseline and follow-up validated outcome measures (e.g., WOMAC, IKDC, VAS), specify PRP formulation (leukocyte-rich vs leukocyte-poor), number and timing of injections, and whether ultrasound guidance was used.
Detail the PRP preparation and administration protocol to address heterogeneity concerns.
Documentation Required
Suggested clinical documentation — include indication, prior treatments, outcomes
Documentation should include indication (e.g., plantar fasciitis, Achilles tendinopathy, rotator cuff pathology, lateral epicondylitis), prior conservative treatments tried, baseline pain/function scores, and description of PRP preparation and administration.
Provide treatment dates, prior therapy responses, and specific injectate and preparation details.
Documentation Required
PRP preparation and composition documentation — record platelet/WBC counts and prep details
Because studies frequently lack detailed PRP composition and standardized preparation protocols, document PRP platelet and white blood cell counts, growth factor data if available, and the preparation method used.
Include device/manufacturer and any activation methods used in PRP preparation documentation.
Documentation Required
Governance, consent, and audit documentation — expect when evidence limited
Where evidence is limited or use is recommended only with special arrangements (per NICE), ensure clinical governance, informed consent, and audit/research documentation are available.
Document consent discussions and participation in registries or research protocols when applicable.
Prior Authorization
Use of policy and governing benefit terms — verify plan requirements
Before applying this policy, verify federal, state, or contractual benefit plan requirements; coverage determination must reference those governing documents.
Provider clinical judgment is used in conjunction with the policy and governing plan terms.
Denial Risk
Denial risk — prolotherapy and PRP considered unproven and not medically necessary
Because prolotherapy and PRP are stated as unproven and not medically necessary for any condition in this policy, claims for these services are at high risk of denial.
Providers should expect investigational/unproven denials unless compelling, documented, plan‑specific coverage criteria are met.
Note
Provider action — miscellaneous
No additional miscellaneous provider action is specified in this segment.
Note
Provider action — miscellaneous
No additional miscellaneous provider action is specified in this segment.
Note
Provider action — miscellaneous
No additional miscellaneous provider action is specified in this segment.
Step Therapy
Evidence context — no defined step therapy algorithms due to heterogeneity
Heterogeneity of evidence, variable PRP preparations, and inconsistent protocols contribute to lack of defined step therapy; no formal algorithms are provided in this excerpt.
Comparators in trials include exercise, saline, PRP, corticosteroids, and HA, but the policy does not set a required sequence.
Studies often enrolled patients refractory to first-line treatments; when available, document prior treatment failure to support consideration of PRP/prolotherapy.
Record duration and outcomes of prior conservative care (PT, NSAIDs, injections).
Step Therapy
No step therapy algorithms described in excerpt
No step therapy algorithms are described in this excerpt.
Documentation Required
Conservative therapy requirement — document failed conservative management before PRP
Providers should document failed conservative management before considering PRP, as many trials and reviews consider PRP/prolotherapy for patients not responding to standard care.
Include duration and specifics of physical therapy, medications, and prior injections.
When PRP is considered, document failure or inadequate response to standard conservative treatments (e.g., PT, NSAIDs, corticosteroid injection) as a prerequisite in the clinical record.
Provide objective baseline and follow-up measures (e.g., VAS, WOMAC) to support claimed benefits.
PRP preparations are heterogeneous and lack standardization in platelet and leukocyte concentrations across studies
Typical usesUsed as intra-articular or peri-tendinous injections and as adjuncts in surgical settings to promote tissue repair
Dextrose prolotherapy (DPT) definition
Dextrose prolotherapy (DPT) — definitionInjection therapy using hypertonic dextrose solutions delivered intra-articularly or peri‑articularly intended to reduce pain and improve function by provoking a local inflammatory healing response
ApplicationsUsed for osteoarthritis and various tendinopathies in clinical trials
AdministrationConcentrations and injection protocols vary across studies (see concentration reporting) and may be ultrasound guided
PRP — autologous blood productPrepared from the patient’s own blood to concentrate platelets and growth factors; intended to stimulate tissue repair and regeneration
Clinical contextUsed in musculoskeletal injections and as surgical adjuncts; studies compare PRP to prolotherapy, HA, steroids, saline, and other treatments
Reporting gapsMany studies do not report PRP composition (platelet count, leukocyte content), limiting reproducibility
Reported dextrose concentrationsVarious concentrations reported including 5%, 15%, 20%, 25%, and 30% in peri‑tendinous or intra‑articular injections
Dose-response notesSome trials compared low (5%) vs higher (15%) concentrations and reported differing short-term efficacy
Protocol variabilityFrequency and number of injections vary (single vs multiple injections at weekly to monthly intervals)
PDRN prolotherapy reference
PDRN prolotherapy — reported usePolydeoxyribonucleotide (PDRN) injections have been reported in case series and retrospective assessments for chronic rotator cuff tendinopathy
Evidence levelLimited data from case series; randomized comparative trials are lacking and further RCTs are required
RecommendationAdditional randomized multidisciplinary trials including imaging outcomes are needed to verify PDRN effectiveness
Prolotherapy summary
Prolotherapy summary — intent and agentsInjections of hypertonic dextrose or sclerosing solutions (and sometimes local anesthetic) into periarticular or intraarticular tissues intended to reduce pain and improve function by inducing a local tissue response
Clinical usesStudied for TMJ disorders, tendinopathies, osteoarthritis, and chronic musculoskeletal pain
Evidence limitationsHeterogeneity in concentrations, injection techniques, and short follow-up in many trials limit generalizability
PRP summary — heterogeneity and evidence
PRP summary — variabilityPRP preparations are heterogeneous, lack standardization (platelet and leukocyte counts vary), and study protocols differ markedly across trials
Clinical findingsSome meta-analyses report short- to mid-term pain/function improvements for select indications (eg, knee OA) but overall evidence quality is low and inconsistent
ImplicationLack of standardization in PRP preparation and reporting limits interpretation and reproducibility of clinical results
Leukocyte-rich vs Leukocyte-poor PRP — distinctions
Leukocyte-rich vs leukocyte-poor PRPPRP formulations are often categorized by leukocyte content (leukocyte-rich [LR-PRP] vs leukocyte-poor [LP-PRP]); LR-PRP has been associated with more local adverse events in some reports
Efficacy comparisonsSome analyses compare LR-PRP and LP-PRP but overall evidence is inconclusive regarding superiority of one formulation
Reporting needStudies should report leukocyte concentration to permit meaningful comparisons
PRP used in injections or adjunct in surgery — variability
PRP clinical applicationsPRP is used for percutaneous injections (intra-articular, peri‑tendinous, intradiscal) and as an adjunct in surgical procedures (eg, rotator cuff repair) — protocols and outcomes vary by application
Adjunct surgical useMeta-analyses suggest PRP may reduce retears after rotator cuff repair and improve short-term outcomes in some studies, but evidence is mixed
Preparation variability impactDifferences in activation, volume, and application method across surgical and injection uses contribute to inconsistent findings
DPT clinical indicationsDextrose prolotherapy has been used in RCTs and observational studies for plantar fasciitis and various tendinopathies (eg, lateral epicondylitis, rotator cuff tendinosis, Achilles) showing short-term improvements in many trials
Comparative outcomesSome trials found DPT superior to saline or exercise at short-term follow-up; results vary by condition and protocol
Evidence gapsSmall sample sizes, heterogeneity of techniques, and variable follow-up durations limit definitive conclusions
PRP composition reporting gaps
PRP composition reporting often missingMany studies omit key composition details such as platelet count, leukocyte content, and growth factor measurements for the PRP preparation
Impact on evidenceIncomplete reporting of PRP composition impedes comparisons between studies and assessment of dose-response relationships
Documentation recommendationTrials and clinical reports should document PRP cell counts and preparation protocols to support reproducibility
PRF / PRP definitions — wound healing adjuncts
PRF / PRP definitions for wound adjunctsPlatelet-rich fibrin (PRF) and PRP are autologous platelet concentrates used as adjuncts to soft tissue regenerative procedures intended to support wound healing and tissue regeneration
Evidence for woundsSystematic reviews report mixed RCT results; some series report positive wound healing events but controlled data are limited
Protocol heterogeneityDifferent preparation and application methods (eg, gel, topical, injection) across wound studies reduce comparability
Prolotherapy definition (hypertonic dextrose)
Prolotherapy (hypertonic dextrose) definitionInjection therapy typically using hypertonic dextrose (and sometimes lidocaine) into joints, ligaments, or tendons to elicit a healing response by provoking a mild inflammatory reaction
Mechanism describedDirected injections aim to 'trick' the body into repairing weakened tissue by promoting new ligament or tendon fiber growth
Common formulationsIncludes inflammatory prolotherapy, growth factor injection prolotherapy, and growth factor stimulation prolotherapy
PRP referenced across multiple RCTs and trials
PRP in trials and reviewsPRP is referenced across numerous randomized trials and multiple systematic reviews/meta-analyses evaluating its use for knee OA, tendinopathies, and other musculoskeletal conditions
Knee OA evidence examplesLarge meta-analyses (eg, Filardo et al.) include many RCTs showing some benefits at 6–12 months but limited by low-quality evidence and heterogeneity
Need for standardizationAuthors repeatedly call for standardized PRP preparation and reporting in future trials
Prolotherapy evidence baseHypertonic dextrose prolotherapy has been evaluated in multiple RCTs and observational studies across indications (eg, lateral epicondylitis, rotator cuff, TMJ, knee OA), often showing short-term symptom improvement
Study limitationsMany studies are small, heterogeneous, and at risk of bias; long-term outcomes beyond 12 months are inconsistently reported
Clinical implicationAlthough some trials report benefit, overall evidence quality and heterogeneity preclude broad coverage conclusions